1 insider has bought $167k of Larimar Therapeutics, Inc. shares across 1 disclosed dealing since July 2026.
| Jul 6, 2026 | Hamilton Thomas Edward — director | $166,890 |
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.